

USES OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN ARTERIOSCLEROSIS

BACKGROUND AND SUMMARY

The present invention relates to a composition containing peroxidic species or oxidation products, its method of preparation, and its use. More specifically, the invention relates to a two-component system of a pharmaceutical formulation which contains: peroxidic species or reaction products resulting from oxidation of an olefinic compound, in a liquid form or in a solution, by an oxygen-containing oxidizing agent; a penetrating solvent; a dye containing a chelated metal; and an aromatic redox compound. The invention also relates to the preparation of the pharmaceutical formulation and its use in treating coronary arteriosclerosis.

Ozone is a triatomic gas molecule and an allotropic form of oxygen. It may be obtained by means of an electrical discharge or intense ultraviolet light through pure oxygen. After the discovery of ozone by Christian Friedrich Schonbein in 1840, six decades passed without any interest in its medical utilization. At the beginning of World War I, Albert Wolf used the gas for the first time therapeutically when it was administered for the topical healing of infected wounds. However, development of medical applications was impeded by the discovery of antibiotic drugs (sulphonamides and penicillins) in the 1920s along with skepticism associated with the internal applications of ozone gas in the field of medicine. For sixty years, ozone clinical research had been limited to European private practice with anecdotal material not published in peer-reviewed journals. Moreover, the popular misconception that ozone is a serious pollutant, the "free radical" theory of disease, and the antioxidant supplement market have comprehensibly prejudiced medical orthodoxy against its use.

Ozone therapy is a misnomer. Ozone is an extremely reactive and unstable gas with mechanisms of action directly related to the by-products that it generates through selective interaction with organic compounds present in the plasma and in the cellular membranes. The selective reaction of ozone with 5 unsaturated olefins occurs at the carbon–carbon double bond, generating ozonides. Ozone is toxic by itself, and its reaction products, ozonides, are unstable and are not therapeutic by themselves.

Hydrogen peroxide (H_2O_2), discovered in 1818, is present in nature in 10 trace amounts. Hydrogen peroxide is unstable and decomposes violently (foams) when in direct contact with organic membranes and particulate matter. Light, agitation, heating, and iron all accelerate the rate of hydrogen peroxide decomposition in solution.

Hydrogen peroxide by direct contact *ex vivo* kills microbes that have 15 low levels of peroxide-destroying enzymes, catalases. For instance, there is no bactericidal effect when hydrogen peroxide is infused into the blood of rabbits infected with peroxide-sensitive *E. coli*. Moreover, increasing the concentration of peroxide *ex-vivo* in rabbit or human blood containing *E. coli* produces no evidence of direct bactericidal activity. The lack of effect of high 20 concentrations of hydrogen peroxide was directly related to the presence of the peroxide-destroying enzyme, catalase. To have any effect, high concentrations of hydrogen peroxide would have to be in contact with the bacteria for significant periods of time. Large amounts of hydrogen peroxide-destroying enzymes, such as catalase, normally present in the blood make it impossible for peroxide to exist in blood for more than a few seconds. One must conclude that 25 hydrogen peroxide introduced into the blood stream by injection or infusion does not directly act as an extracellular germicide in blood or extracellular fluids.

However, hydrogen peroxide does participate in the bactericidal processes within activated macrophage cells. The critical therapeutic criteria

for intracellular peroxidation are the selective delivery, absorption and activation of peroxidic carrier molecules into only diseased macrophages, which are believed to be incapable of upgraded catalase and glutathione reductase activity. Infused hydrogen peroxide is a generalized poison whereas targeted intracellular peroxidation is a selective therapeutic tool.

5

U.S. Patent No. 4,451,480 to De Villez teaches a composition and method for treating acne. The method includes topically treating the affected area with an ozonized material derived from ozonizing various fixed oil and unsaturated esters, alcohols, ethers and fatty acids.

10

U.S. Patent No. 4,591,602 to De Villez shows an ozonide of Jojoba used to control microbial infections.

U.S. Patent No. 4,983,637 to Herman discloses a method to parenterally treat local and systemic viral infections by administering ozonides of terpenes in a pharmaceutically acceptable carrier.

15

U.S. Patent No. 5,086,076 to Herman shows an antiviral composition containing a carrier and an ozonide of a terpene. The composition is suitable for systemic administration or local application.

U.S. Patent No. 5,126,376 to Herman describes a method to topically treat a viral infection in a mammal using an ozonide of a terpene in a carrier.

20

U.S. Patent No. 5,190,977 to Herman teaches an antiviral composition containing a non-aqueous carrier and an ozonide of a terpene suitable for systemic injection.

U.S. Patent No. 5,190,979 to Herman describes a method to parenterally treat a medical condition in a mammal using an ozonide of a terpene in a carrier.

25

U.S. Patent No. 5,260,342 to Herman teaches a method to parenterally treat viral infections in a mammal using an ozonide of a terpene in a carrier.

U.S. Patent No. 5,270,344 to Herman shows a method to treat a systemic disorder in a mammal by applying to the intestine of the mammal a trioxolane or a diperoxide derivative of an unsaturated hydrocarbon which derivative is prepared by ozonizing the unsaturated hydrocarbon dissolved in a non-polar solvent.

5

U.S. Patent No. 5,364,879 to Herman describes a composition for the treatment of a medical condition in a mammal, the composition contains a diperoxide or trioxolane derivative of a non-terpene unsaturated hydrocarbon which derivative is prepared by ozonizing below 35° C the unsaturated hydrocarbon in a carrier.

10

Despite the reports on the use of terpene ozonides for different medical indications, terpene ozonides display multiple deficiencies. For example, ozonides of monoterpane, such as myrcene and limonene, flamed out in the laboratory. Consequently, they would be too dangerous to formulate or store.

15

Furthermore, ozonides of geraniol, a linear monoterpane alcohol, in water or in DMSO did not show any clinical efficacy in three case of viral Varicella Zoster (shingles) and two cases of Herpes Simplex dermatitis.

20

Coronary heart disease ("CHD") is the single largest killer in the U.S. It affects about 12 million people in this country. It is responsible for 1 out of 5 deaths, totaling nearly about half a million a year. The disease is caused by a narrowing of the large arteries by plaques made up of blood fats, such as cholesterol, smooth muscle cells, collagen and other proteins, and even calcium deposits. The narrowing of the arteries in turn hamper the supply of blood to the heart muscle. CHD can cause angina, which involves episodes of chest pain due to decrease supply of blood flow and oxygen to the heart muscle. About 6.3 million Americans suffer from angina. CHD can lead to myocardial infarctions, commonly known as heart attacks where tissues in portions of a heart die because of inadequate blood supply. This occurs when one of the coronary arteries becomes completely blocked. Heart attacks affect over 1

25

million of Americans each year. When the heart muscle is damaged, it has problems pumping blood efficiently, causing congestive heart failure, which affects about 5.6 million Americans. Then, about 4.3 million Americans have heart rhythm disturbances, which are known as arrhythmias.

5 There is, therefore, a pressing need for new and curative treatments for these diseases.

DETAILED DESCRIPTION

The present invention relates to compositions comprising peroxidic species or reaction products resulting from oxidation of an unsaturated organic compound, in a liquid form or in a solution, by an oxygen-containing oxidizing agent; a penetrating solvent; a chelated dye; and an aromatic redox compound. 5 In one embodiment of the present invention, the essential components include the peroxidic products formed by ozonolysis of an unsaturated alcohol, a stabilizing solvent, metalloporphyrin, and quinone.

10 The unsaturated organic compound, or the unsaturated olefinic hydrocarbon, for the present invention can be an alkene without a hydroxyl group, or a hydroxyl-containing alkene. Thus, the alkene without a hydroxyl group may be an open-chain unsaturated hydrocarbon, a monocyclic unsaturated hydrocarbon, or a bicyclic unsaturated hydrocarbon. The hydroxyl-containing alkene can be an open-chain unsaturated alcohol, a monocyclic 15 unsaturated alcohol, or a bicyclic unsaturated alcohol.

The unsaturated organic compound may be linear, branched, cyclic, spiral, or complexed with other molecules in its configuration. The unsaturated organic compound may naturally exist in a gaseous liquid or solid state prior to binding with the "activated oxygen."

20 An open-chain unsaturated hydrocarbons can be: C_nH_{2n} , one double bond, $n=2-20$; C_nH_{2n-2} , two double bonds, $n=4-20$; C_nH_{2n-4} , three double bonds, $n=6-20$; C_nH_{2n-6} , four double bonds, $n=8-20$; $C_{25}H_{40}$, sesterterpene hydrocarbon; or $C_{30}H_{48}$, triterpene hydrocarbon.

25 A monocyclic unsaturated hydrocarbon can be: C_nH_{2n-2} , one double bond + one ring, $n=3-20$; C_nH_{2n-4} , two double bonds + one ring, $n=5-20$; C_nH_{2n-6} , three double bonds + one ring, $n=7-20$; $C_{25}H_{40}$, sesterterpene hydrocarbon; or $C_{30}H_{48}$, triterpene hydrocarbon.

A bicyclic unsaturated hydrocarbon can be: C_nH_{2n-4} , one double bond + two rings, n=4-20; C_nH_{2n-6} , two double bonds + two rings, n=6-20; $C_{25}H_{40}$, sesterterpene hydrocarbon; or $C_{30}H_{48}$, triterpene hydrocarbons.

An open-chain unsaturated alcohol can be: $C_nH_{2n}O_m$, one double bond, 5 n=3-20, m=1-4; $C_nH_{2n-2}O_m$, two double bonds, n=5-20, m=1-4; $C_nH_{2n-4}O_m$, three double bonds, n=7-20, m=1-4; $C_nH_{2n-6}O_m$, four double bonds, n=9-20, m=1-4; $C_{25}H_{40}O_m$, m=1-4, sesterterpene alcohols; or $C_{30}H_{48}O_m$, m=1-4, triterpene alcohols.

A monocyclic unsaturated alcohol can be: $C_nH_{2n-2}O_m$, one double bond 10 + one ring, n=3-20, m=1-4; $C_nH_{2n-4}O_m$, two double bonds + one ring, n=5-20, m=1-4; $C_nH_{2n-6}O_m$, three double bonds + one ring, n=7-20, m=1-4; $C_{25}H_{40}O_m$, m=1-4, sesterterpene alcohols; or $C_{30}H_{48}O_m$, m=1-4, triterpene alcohols.

A bicyclic unsaturated alcohol can be: $C_nH_{2n-4}O_m$, one double bond + two rings, n=5-20, m=1-4; $C_nH_{2n-6}O_m$, two double bonds + two rings, n=7-20, 15 m=1-4; $C_{25}H_{40}O_m$, m=1-4, sesterterpene alcohols; or $C_{30}H_{48}O_m$, m=1-4, triterpene alcohols.

Usable unsaturated olefinic hydrocarbons may be unsubstituted, substituted, cyclic or complexed alkenes, hydrazines, isoprenoids, steroids, quinolines, carotenoids, tocopherols, prenylated proteins, or unsaturated fats. 20 The preferred unsaturated hydrocarbons for this invention are alkenes and isoprenoids. The more preferred unsaturated hydrocarbons for this invention are linear isoprenoid alcohols with two to four repeating isoprene groups in a linear chain, such as geraniol, geranylgeraniol, nerol, or linalool.

Isoprenoids are found primarily in plants as constituents of essential oils. 25 While many isoprenoids are hydrocarbons, oxygen-containing isoprenoids also occur such as alcohols, aldehydes, and ketones. In a formal sense, the building block of isoprenoid hydrocarbons may be envisaged as the hydrocarbon isoprene, $CH_2=C(CH_3)-CH=CH_2$, although it is known that isoprene itself is an

end-product of isoprenoid biosynthesis and not an intermediate. Isoprenoid hydrocarbons are categorized by the number of isoprene (C_5H_8) units they contain. Thus, monoterpenes have 2, sesquiterpenes have 3, diterpenes have 4, sesterterpenes have 5, triterpenes have 6, and tetraterpenes have 8 isoprene units, respectively. Tetraterpenes are much more commonly known as carotenoids.

Limonene and pinene are examples of a monoterpene. Farnesol and nerolidol are examples of a sesquiterpene alcohol. Vitamin A₁ and phytol are examples of a diterpene alcohol while squalene is an example of a triterpene. Provitamin A₁, known as carotene, is an example of a tetraterpene. Geraniol, a monoterpene alcohol, is liquid in both its oxygen bound and normal states and is safe to living cells.

Based on the total weight of the pharmaceutical formulation, the alkene can vary from about 0.001% to about 30%, preferably from about 0.1% to about 5.0%, and more preferably from about 0.5% to about 3.0%.

The oxygen-containing oxidizing agents for reaction to the unsaturated hydrocarbon may be singlet oxygen, oxygen in its triplet state, superoxide anion, ozone, periodate, hydroxyl radical, hydrogen peroxide, alkyl peroxide, carbamyl peroxide, benzoyl peroxide, or oxygen bound to a transition element, such as molybdenum (e.g. MoO₅).

The preferred oxygen-containing oxidizing agents for this invention include ozone, singlet oxygen, and superoxide anion. Ozone is the most preferred oxygen-containing oxidizing agent for binding to the unsaturated hydrocarbon. It is prepared from pure oxygen.


We found that the best method to bind “activated oxygen” to intact geraniol is by ozonation at temperatures between 0-20° C in the dark in the absence of water or polar solvent. The geraniol “ozonides” were then dissolved and stabilized in 100 % dimethylsulfoxide (DMSO) in the dark to prevent

premature breakdown of the products. Although not wanting to be bound by any theory, it is believed that the catalytic breakdown of the tetraoxane peroxidic dimer byproduct of geraniol ozonation, which is not an ozonide, occurs inside of cells in the presence of superoxide anion. The final reactive therapeutic agents released are hydrogen peroxide and acetic acid.

5


Although not wanting to be bound by theory, it is believed that, in general, the reaction between an alkene and ozone in this application proceeds by the Criegee mechanism. According to this mechanism, the initial step of the reaction is a 1,3-dipolar cycloaddition of ozone to the alkene to give a primary ozonide (a 1,2,3-trioxalane). The primary ozonide is unstable and undergoes a 1,3-cycloreversion with the carbonyl compound to give the "normal" ozonide, a 1,2,4-trioxalane.

10




15

In a side reaction, the carbonyl oxide can enter into a dimerization to give a peroxidic dimer, the 1,2,4,5-tetraoxane.



The carbonyl oxide is a strongly electrophilic species, and in the presence of nucleophilic species (e.g. alcohols or water), it undergoes facile nucleophilic addition to give a 1-alkoxyhydroperoxide. Under certain

conditions, the 1-alkoxyhydroperoxide can undergo further reaction to give carboxylic acid derivatives.



SCHEME 3

Again, not wanting to be bound by theory, it is believed that during the ozonolysis of the alcohol-containing alkene in the present invention, it is reasonable to expect that three major types of peroxidic products will be present: the normal ozonide, the carbonyl tetraoxane dimer, and the 1-alkoxyhydroperoxide. In the presence of water, some of these peroxidic products may also lead to the presence of organic peracids in the crude product mixture.

The present invention involves the use of DMSO to "stabilize" the initial products of the ozonolysis. Similarly, not wanting to be bound by any theory, it is believed that the stabilization is most likely a simple solvation phenomenon. However, dimethyl sulfoxide is known to be a nucleophile in its own right. Its participation is also possible. as a nucleophilic partner in stabilizing reactive species (for example, as dimethylsulfoxonium salts).

The penetrating solvent for the oxygen-bound unsaturated hydrocarbon may be an emollient, a liquid, a membrane, a micelle, a plasma or a vapor.

Usable penetrating solvents are water, fats, sterols, lecithins, phosphatides, pH-buffered saline, ethanol, propylene glycol, dimethyl sulfoxide, methylsulfonylmethane, and polyvinylpyrrolidine. The preferred penetrating solvents include dimethylsulfoxide, polyvinylpyrrolidine, and pH-buffered saline. The most preferred penetrating solvent includes dimethylsulfoxide.

Based on the total weight of the pharmaceutical formulation, the penetrating solvent can vary from about 50% to about 99 %, preferably from about 90% to about 98%, and more preferably from about 95% to about 98%.

5 The "stabilized" peroxidic molecule and its penetrating solvent have been made from components currently used in production regulated by the Food and Drug Administration ("FDA"). These ingredients are the subject of Drug Master Files, Drug Monographs, are found in the USP/NF, or are Generally Recognized As Safe ("GRAS"). The superoxide generating dye and perpetuating agent, also biologically compatible, probably conveniently form a
10 molecular complex.

15 The other components of the pharmaceutical formulation can include the metalloporphyrin and quinone. The propensity of metalloporphyrins to sensitize oxygen under photochemical excitation is well documented as is the propensity of ferroporphyrins and copper porphyrins to bind oxygen-containing systems.

20 Researchers of photodynamic therapy have known that the superoxide dye and the perpetuator selectively absorb into infected and dysplastic cells. These diseased cells are fortuitously both catalase deficient. The electronic activation of the dye and perpetuator simply requires a milli-volt AC pulse. This requisite pulse is conveniently provided by a beating heart. Moreover, normal cells are not harmed.

25 Usable dyes, include natural or synthetic dyes. Examples include porphyrins, rose bengal, chlorophyllins, hemins, porphins, corrins, texaphrins, methylene blue, hematoxylin, eosin, erythrosin, flavinoids, lactoflavin, anthracene dyes, hypericin, methylcholanthrene, neutral red, and fluorescein.

For this invention, the preferred dyes can be any natural or synthetic porphyrin, hematoporphyrin, chlorophyllin, rose bengal, their respective

congeners, or a combination thereof. The most preferred dyes are naturally occurring porphyrins, such as hematoporphyrin, and rose bengal.

Based on the total weight of the pharmaceutical formulation or composition, the dye can vary from about 0.1 % to about 30 %, preferably from 5 about 0.5 % to about 5 %, and more preferably from about 0.8 % to about 1.5 %.

The dye may be responsive to photon; laser; ionizing radiation; phonon; electrical cardiac electroporation; magnetic or plasma pulse; or continuous flow excitation.

10 The aromatic redox compound includes any substituted or unsubstituted benzoquinone, naphthoquinone, or anthroquinone. The preferred aromatic redox compound includes benzoquinone, methyl-benzoquinone, naphthoquinone, and methyl-naphthoquinone. The most preferred aromatic redox compound includes substituted or unsubstituted benzoquinone and 15 naphthoquinone.

Based on the total weight of the pharmaceutical formulation, the aromatic redox compound can vary from about 0.01 % to about 20.0%, preferably from about 0.1 % to about 10 %, and more preferably from about 0.1 % to about 0.5%.

20 Useful electron donors for this invention include plasma, an electrical current, ascorbate, and germanium sesquioxide. Preferred electron donors include ascorbate and germanium sesquioxide. The most preferred electron donor is ascorbate in any salt form.

25 Based on the total weight of the pharmaceutical formulation, the electron donor can vary from about 0.01 % to about 20 %, preferably from about 1 % to about 10 %, and more preferably from about 1 % to about 5 %.

In order to obtain a biological effect *in vivo*, it is necessary to infuse an ozonolysis peroxidic tetraoxane product of a terpene alcohol, rather than an ozonide, in conjunction with a superoxide generating metallo-porphyrin dye and an aromatic quinone.

5 Although not wanted to be bound by any theory, it is postulated that the preferred pharmaceutical formulation is a combination of biochemical agents that induce recycling autocatalytic oxidation in infected or dysplastic macrophages. The recycling autocatalytic oxidation stimulates targeted apoptosis (cell suicide) through peroxidation.

10 The pharmaceutical formulation of this invention as described in Example 3B ("Terphorone") was utilized to treat patients with coronary artery disease. For the patient studies, the dose was case specific. Generally, it was 1.0 cc of Terphorone per 70 kg of body weight. The schedules could be 2 infusions monthly for 6 months, then 2 infusions every 3 months for 2 years, 15 and the route of administration was preferably i.v., although other routes of administration were possible.

EXAMPLE 1

20 Ozonolysis of an alkene may be carried out either in a solvent or neat. In either case, the cooling of the reaction mixture is critical in avoiding explosive decomposition of the peroxidic products of the reaction.

The following general procedure is typical for the ozonolysis of a liquid alkene.

25 A 1-liter flask fitted with a magnetic stirrer is charged with the alkene (2 moles), and the apparatus is weighed. The flask is surrounded by a cooling bath (ice-water or ice-salt). Once the contents are cooled below 5°C, stirring is begun and a stream of ozone in dry oxygen (typically 3% ozone) is passed through the mixture. It is advantageous to disperse the ozonated oxygen

through a glass frit, but this is not necessary for a stirred solution. Periodically, the gas stream is stopped, and the reaction flask is weighed or the reaction mixture is sampled. The gas stream is then re-started.

5 Once the mass of the reaction flask shows sufficient weight gain, or once the proton magnetic resonance ("H¹ NMR") spectrum of the reaction mixture shows the desired reduction in the intensity of the olefinic proton resonances (usually about 50%), the gas flow is stopped.

10 The ozonolysis may be carried out as above, substituting a solution of the alkene in a solvent non-reactive towards ozone such as saturated hydrocarbons or chlorinated hydrocarbons.

15 The ozonolysis may be carried out as above, with or without solvent, substituting an alkenol for the alkene without affecting the reaction in any substantive manner.

15 The reaction mixture is then poured slowly into the cooled penetrating solvent.

EXAMPLE 2

A preferred pharmaceutical formulation of the present invention was prepared as follows:

20 (1) Sparging an ozone/pure oxygen gas mixture of 120 mg/L up through an alkadiene alcohol, 3,7-dimethyl-2,6-octadien-1-ol (geraniol), at 1 Liter of gas per hour;

(2) Maintaining the temperature of the reaction around 5° C;

(3) Removing small aliquots of reaction product hourly and measuring by H¹ NMR the formation of the peroxidic species or reaction products;

0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
229
230
231
232
233
234
235
236
237
238
239
239
240
241
242
243
244
245
246
247
248
249
249
250
251
252
253
254
255
256
257
258
259
259
260
261
262
263
264
265
266
267
268
269
269
270
271
272
273
274
275
276
277
278
279
279
280
281
282
283
284
285
286
287
287
288
289
289
290
291
292
293
293
294
295
295
296
297
297
298
299
299
300
301
302
303
303
304
305
305
306
307
307
308
309
309
310
311
311
312
313
313
314
315
315
316
317
317
318
319
319
320
321
321
322
323
323
324
325
325
326
327
327
328
329
329
330
331
331
332
333
333
334
335
335
336
337
337
338
339
339
340
341
341
342
343
343
344
345
345
346
347
347
348
349
349
350
351
351
352
353
353
354
355
355
356
357
357
358
359
359
360
361
361
362
363
363
364
365
365
366
367
367
368
369
369
370
371
371
372
373
373
374
375
375
376
377
377
378
379
379
380
381
381
382
383
383
384
385
385
386
387
387
388
389
389
390
391
391
392
393
393
394
395
395
396
397
397
398
399
399
400
401
401
402
403
403
404
405
405
406
407
407
408
409
409
410
411
411
412
413
413
414
415
415
416
417
417
418
419
419
420
421
421
422
423
423
424
425
425
426
427
427
428
429
429
430
431
431
432
433
433
434
435
435
436
437
437
438
439
439
440
441
441
442
443
443
444
445
445
446
447
447
448
449
449
450
451
451
452
453
453
454
455
455
456
457
457
458
459
459
460
461
461
462
463
463
464
465
465
466
467
467
468
469
469
470
471
471
472
473
473
474
475
475
476
477
477
478
479
479
480
481
481
482
483
483
484
485
485
486
487
487
488
489
489
490
491
491
492
493
493
494
495
495
496
497
497
498
499
499
500
501
501
502
503
503
504
505
505
506
507
507
508
509
509
510
511
511
512
513
513
514
515
515
516
517
517
518
519
519
520
521
521
522
523
523
524
525
525
526
527
527
528
529
529
530
531
531
532
533
533
534
535
535
536
537
537
538
539
539
540
541
541
542
543
543
544
545
545
546
547
547
548
549
549
550
551
551
552
553
553
554
555
555
556
557
557
558
559
559
560
561
561
562
563
563
564
565
565
566
567
567
568
569
569
570
571
571
572
573
573
574
575
575
576
577
577
578
579
579
580
581
581
582
583
583
584
585
585
586
587
587
588
589
589
590
591
591
592
593
593
594
595
595
596
597
597
598
599
599
600
601
601
602
603
603
604
605
605
606
607
607
608
609
609
610
611
611
612
613
613
614
615
615
616
617
617
618
619
619
620
621
621
622
623
623
624
625
625
626
627
627
628
629
629
630
631
631
632
633
633
634
635
635
636
637
637
638
639
639
640
641
641
642
643
643
644
645
645
646
647
647
648
649
649
650
651
651
652
653
653
654
655
655
656
657
657
658
659
659
660
661
661
662
663
663
664
665
665
666
667
667
668
669
669
670
671
671
672
673
673
674
675
675
676
677
677
678
679
679
680
681
681
682
683
683
684
685
685
686
687
687
688
689
689
690
691
691
692
693
693
694
695
695
696
697
697
698
699
699
700
701
701
702
703
703
704
705
705
706
707
707
708
709
709
710
711
711
712
713
713
714
715
715
716
717
717
718
719
719
720
721
721
722
723
723
724
725
725
726
727
727
728
729
729
730
731
731
732
733
733
734
735
735
736
737
737
738
739
739
740
741
741
742
743
743
744
745
745
746
747
747
748
749
749
750
751
751
752
753
753
754
755
755
756
757
757
758
759
759
760
761
761
762
763
763
764
765
765
766
767
767
768
769
769
770
771
771
772
773
773
774
775
775
776
777
777
778
779
779
780
781
781
782
783
783
784
785
785
786
787
787
788
789
789
790
791
791
792
793
793
794
795
795
796
797
797
798
799
799
800
801
801
802
803
803
804
805
805
806
807
807
808
809
809
810
811
811
812
813
813
814
815
815
816
817
817
818
819
819
820
821
821
822
823
823
824
825
825
826
827
827
828
829
829
830
831
831
832
833
833
834
835
835
836
837
837
838
839
839
840
841
841
842
843
843
844
845
845
846
847
847
848
849
849
850
851
851
852
853
853
854
855
855
856
857
857
858
859
859
860
861
861
862
863
863
864
865
865
866
867
867
868
869
869
870
871
871
872
873
873
874
875
875
876
877
877
878
879
879
880
881
881
882
883
883
884
885
885
886
887
887
888
889
889
890
891
891
892
893
893
894
895
895
896
897
897
898
899
899
900
901
901
902
903
903
904
905
905
906
907
907
908
909
909
910
911
911
912
913
913
914
915
915
916
917
917
918
919
919
920
921
921
922
923
923
924
925
925
926
927
927
928
929
929
930
931
931
932
933
933
934
935
935
936
937
937
938
939
939
940
941
941
942
943
943
944
945
945
946
947
947
948
949
949
950
951
951
952
953
953
954
955
955
956
957
957
958
959
959
960
961
961
962
963
963
964
965
965
966
967
967
968
969
969
970
971
971
972
973
973
974
975
975
976
977
977
978
979
979
980
981
981
982
983
983
984
985
985
986
987
987
988
989
989
990
991
991
992
993
993
994
995
995
996
997
997
998
999
999
1000
1001
1001
1002
1003
1003
1004
1005
1005
1006
1007
1007
1008
1009
1009
10010
10011
10011
10012
10013
10013
10014
10015
10015
10016
10017
10017
10018
10019
10019
10020
10021
10021
10022
10023
10023
10024
10025
10025
10026
10027
10027
10028
10029
10029
10030
10031
10031
10032
10033
10033
10034
10035
10035
10036
10037
10037
10038
10039
10039
10040
10041
10041
10042
10043
10043
10044
10045
10045
10046
10047
10047
10048
10049
10049
10050
10051
10051
10052
10053
10053
10054
10055
10055
10056
10057
10057
10058
10059
10059
10060
10061
10061
10062
10063
10063
10064
10065
10065
10066
10067
10067
10068
10069
10069
10070
10071
10071
10072
10073
10073
10074
10075
10075
10076
10077
10077
10078
10079
10079
10080
10081
10081
10082
10083
10083
10084
10085
10085
10086
10087
10087
10088
10089
10089
10090
10091
10091
10092
10093
10093
10094
10095
10095
10096
10097
10097
10098
10099
10099
100100
100101
100101
100102
100103
100103
100104
100105
100105
100106
100107
100107
100108
100109
100109
100110
100111
100111
100112
100113
100113
100114
100115
100115
100116
100117
100117
100118
100119
100119
100120
100121
100121
100122
100123
100123
100124
100125
100125
100126
100127
100127
100128
100129
100129
100130
100131
100131
100132
100133
100133
100134
100135
100135
100136
100137
100137
100138
100139
100139
100140
100141
100141
100142
100143
100143
100144
100145
100145
100146
100147
100147
100148
100149
100149
100150
100151
100151
100152
100153
100153
100154
100155
100155
100156
100157
100157
100158
100159
100159
100160
100161
100161
100162
100163
100163
100164
100165
100165
100166
100167
100167
100168
100169
100169
100170
100171
100171
100172
100173
100173
100174
100175
100175
100176
100177
100177
100178
100179
100179
100180
100181
100181
100182
100183
100183
100184
100185
100185
100186
100187
100187
100188
100189
100189
100190
100191
100191
100192
100193
100193
100194
100195
100195
100196
100197
100197
100198
100199
100199
100200
100201
100201
100202
100203
100203
100204
100205
100205
100206
100207
100207
100208
100209
100209
100210
100211
100211
100212
100213
100213
100214
100215
100215
100216
100217
100217
100218
100219
100219
100220
100221
100221
100222
100223
100223
100224
100225
100225
100226
100227
100227
100228
100229
100229
100230
100231
100231
100232
100233
100233
100234
100235
100235
100236
100237
100237
100238
100239
100239
100240
100241
100241
100242
100243
100243
100244
100245
100245
100246
100247
100247
100248
100249
100249
100250
100251
100251
100252
100253
100253
100254
100255
100255
100256
100257
100257
100258
100259
100259
100260
100261
100261
100262
100263
100263
100264
100265
100265
100266
100267
100267
100268
100269
100269
100270
100271
100271
100272
100273
100273
100274
100275
100275
100276
100277
100277
100278
100279
100279
100280
100281
100281
100282
100283
100283
100284
100285
100285
100286
100287
100287
100288
100289
100289
100290
100291
100291
100292
100293
100293
100294
100295
100295
100296
100297
100297
100298
100299
100299
100300
100301
100301
100302
100303
100303
100304
100305
100305
100306
100307
100307
100308
100309
100309
100310
100311
100311
100312
100313
100313
100314
100315
100315
100316
100317
100317
100318
100319
100319
100320
100321
100321
100322
100323
100323
100324
100325
100325
100326
100327
100327
100328
100329
100329
100330
100331
100331
100332
100333
100333
100334
100335
100335
100336
100337
100337
100338
100339
100339
100340
100341
100341
100342
100343
100343
100344
100345
100345
100346
100347
100347
100348
100349
100349
100350
100351
100351
100352
100353
100353
100354
100355
100355
100356
100357
100357
100358
100359
100359
100360
100361
100361
100362
100363
100363
100364
100365
100365
100366
100367
100367
100368
100369
100369
100370
100371
100371
100372
100373
100373
100374
100375
100375
100376
100377
100377
100378
100379
100379
100380
100381
100381
100382
100383
100383
100384
100385
100385
100386
100387
100387
100388
100389
100389
100390
100391
100391
100392
100393
100393
100394
100395
100395
100396
100397
100397
100398
100399
100399
100400
100401
100401
10

B.

WEIGHT % INGREDIENT

0.54*	Tetraoxane dimer of acetal peroxide from ozonization of geraniol.
98.00	DMSO
0.83	Hematoporphyrin
0.24	Methylnaphthoquinone
0.39	Chlorophyllin Sodium-Copper Salt

*Determined by mass spectroscopy.

EXAMPLE 4

The pharmaceutical formulation of the present invention can be incorporated into a premixed solvent. This formulation is very stable and exhibited the same minimal toxicity profile and clinical efficacy after more than a year of storage. Moreover, to avoid the stability issue entirely, the formulation can be packaged in a two-vial system. More specifically, the package consists of a small box containing the following:

10 (1) Vial of liquid phase containing: (a) the peroxidic species or reaction products resulting from oxidation of an alkene in a liquid form or in a solution, by an oxidizing agent; and (b) a penetrating solvent.

15 (2) Vial of relatively dry solid relatively dry phase containing: (a) a dye containing a chelated divalent or trivalent metal; and (b) an aromatic redox compound.

(3) An optional mixing needle.

(4) An optional package insert.

20 The liquid phase is introduced into the vial of solid phase and then shaken to mix. The pharmaceutical formulation of the present invention is thus

reconstituted at the patient's side. Thus, the stability of the formulation is greatly enhanced.

EXAMPLE 5

A 63-year old Caucasian female with a medical history of a two-vessel coronary artery bypass graft ("CABG") in 1996, followed by repeat of mammary artery graft in March 2000. Her left main coronary artery stenosis could not be addressed at the time of the second surgery, as her vessels were deemed too small to bypass or stent. Within six weeks of mammary artery graft, the patient was advised that this graft had re-blocked secondary to "scar formation". The patient was scheduled for internal and external X-irradiation of coronary grafts to control scar formation. The patient is a known keloid scar former. The vein graft donor site from the left forearm had formed extensive keloid from wrist to elbow, approximately 10.5 cm. x 1.5 cm. The patient opted to consider bio-oxidative non-invasive treatment. Prior to infusions of the Terphorone, the patient reported using up to 30 sublingual nitroglycerine ("NTG") sublingual tablets per week. She averaged a trip to the emergency room every two to three weeks for i.v. NTG infusion to resolve angina. These trips included three to four day follow-up stays in the I.C.U. Since about 8 months ago, the patient has received six doses of the Terphorone. The dose was 1 cc of Terphorone diluted in 100 cc of sterile normal saline, infused over 20 minutes. Her sublingual angina therapy was down to one per week, with most weeks requiring no NTG at all. She has not been to the hospital for i.v. anti-angina NTG infusion since receiving her first infusion of the preferred formulation described in Example 3B. Moreover, the patient's keloid from her graft donor site on the left forearm virtually disappeared following her first two doses of the Terphorone.

EXAMPLE 6

A 62-year old Caucasian male with a medical history of multiple-vessel coronary artery bypass graft ("CABG") surgery twice in 1994. Increasing angina brought the patient to treatment in October 1999. The patient required an NTG patch (0.4 mg/hr) daily to relieve both stable and unstable angina. Physical activity was limited to nearly zero at that time. The patient's cardiologist recommended another repeat bypass at that time. Since October 1999, the patient has received 20 i.v. 0.5 cc doses of the Terphorone which formulation is described in Example 3B. The dosage was 0.5 cc progressing to 1.0 cc in 0.1 cc steps, diluted in 100 cc sterile normal saline, infused over 20 minutes. The patient's angina has totally subsided both at rest and with routine exercise. He no longer requires an NTG patch. He now plays golf and walks the course four to six times per week. The only setback this patient has had during his course of oxidative therapy came when his cardiologist diagnosed him with atrial fibrillation of new onset in early 2000. The cardiologist placed the patient on Coumadin (anticoagulant). Terphorone treatment was terminated temporarily, due to its contraindication with Coumadin therapy. When the atrial fibrillation resolved, the patient was weaned off of Coumadin and Terphorone treatments were resumed. The patient is symptom free with a normal cardiac conduction at this time.

EXAMPLE 7

A 50-year old Caucasian male first seen in the emergency room with chest pain in 1996. The EKG showed nonspecific ST-T wave changes. The patient was scheduled for coronary angiogram with angioplasty, but he refused the procedure. The subjective complaint made by the patient was primarily severe chest pain on exertion. His job required climbing ladders up three story buildings for the inspection of air conditioning equipment. The patient complained that chest pain was so severe upon reaching the top of the buildings that he would have to rest in a supine position for varying amounts of time

before resuming work. The angina was relieved with sublingual NTG. Since about 11 months ago, the patient has received six intravenous doses of Terphorone. The dosage was 0.5 cc progressing to 1.0 cc in 0.1 cc steps, diluted in 100 cc sterile normal saline, infused over 20 minutes. Angina has completely 5 subsided, even on extreme exertion. The patient continues to accomplish the same work he was doing prior to treatment, now without incident. He has not required sublingual NTG since initiation of Terphorone therapy.

EXAMPLE 8

A 47-year old Caucasian male had a history of multiple M.I.s. He 10 reported having an M.I. every six months to one year for the five years leading up to his CABG (x4) in 1996. The patient was discharged from the military under full disability secondary to the cardiac condition. The patient required NTG paste on his chest during sex leading up to and following CABG surgery. Before being examined for this experiment, the patient's cardiologist at a 15 hospital had recommended a heart transplant. He had five or six Thallium stress tests performed on him in the year preceding his participation in this trial. All of these tests were positive for multiple vessel disease. Since about 1.5 years ago, the patient has received eight doses of Terphorone. The dosage was 0.5 cc progressing to 1.0 cc in 0.1 cc steps, diluted in 100 cc sterile normal saline, 20 infused over 20 minutes. He no longer requires NTG paste during sex. He is able now to do exertion, such as mowing his lawn, without chest pain. His cardiologist still maintains that he needs a heart transplant. The patient's only medications at this time are a long-acting vasodilator once a day by mouth and a low dose ACE inhibitor once daily.

EXAMPLE 9

An 89-year old Caucasian male had a history of transient ischemic attacks. He had right carotid artery arteriosclerosis, reported to be an 85% blockage by direct imaging. The patient had been in atrial fibrillation for approximately one year and was taking Rhythmol. He also reported extreme lethargy on a daily basis. He reported some disorientation on occasion and had had some falls in the past. The vascular surgeon recommended immediate carotid endarterectomy. The patient opted for alternative non-invasive treatment. Since September 2000, the patient has received 4 doses of Terphorone. The dosage was 0.5 cc progressing to 1.0 cc in 0.1 cc steps, diluted in 100 cc sterile normal saline, infused over 20 minutes. His general stamina has increased by at least 50%, according to his caretaker. The patient was placed on a 24 hour Holter monitor two weeks following his first two Terphorone infusions. His atrial fibrillation had resolved. Although he was weaned off of his Rhythmol, the atrial fibrillation had not returned. The patient has not had a transient ischemic attack since initiation of Terphorone therapy. In early November 2000, he went on a seven-day cruise with his family without incident.

EXAMPLE 10

Ozone at a concentration of 120 mcg/ml at 1/8 L/min was sparged up through 100 ml of 100% myrcene liquid at 5° C, and the vapor was allowed to enter the atmosphere. Static electricity from the chemist set off an explosive flame in the vapor.

Ozonated limonene was created by the same method with precautions against spark generation. The ozonide product was stored in a closet at room temperature in a sealed brown bottle overnight. The next morning the chemist and pharmacist saw fine glass powder and a syrupy chemical splashed inside the closet.

EXAMPLE 11

Ozone (120 micrograms/ml) was bubbled up through 1 L of neat geraniol at 5° C for 48 hours. The reaction products were diluted 1:9 with DMSO to give a product mixture.

5 The mixture at 3% was administered intravenously to a patient suffering from Herpes (Varicella) Zoster daily for 3 consecutive days. There was no observable effect or improvement on the patient's Herpes (Varicella) Zoster.

10 The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.